Meta Analysis of Efficacy and Safety of Ribavirin in the Treatment of COVID-19

doi:10.19803/j.1672-8629.2020.07.03

Abstract

Abstract: Objective To evaluate the efficacy and safety of ribavirin for COVID-19 by systematically reviewing previous clinical studies of coronavirus pneumonia. Methods Such databases as Pubmed, EMbase, Cochrane Library, Google Scholar, CNKI, Wanfang Data, VIP and CBM were searched. The date of the latest search was April 29, 2020. Clinical studies on ribavirin used in the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) were included. The literature was screened according to the inclusion and exclusion criteria and the methodological quality of the included studies was assessed by two reviewers independently. Meta-analysis was performed using Review Manager 5.3 software. Results In total, 7 studies were included, resulting in a sample size of 870 cases. The overall pooled data demonstrated that the difference in mortality rates between the ribavirin group and control group was not statistically significant in the treatment of SARS and MERS[OR=1.10,95％CI（0.79,1.55）,P=0.57]. In the subgroup analysis, the mortality rate was not significantly different between the ribavirin group and control group in the treatment of SARS and MERS whether ribavirin was combined with interferon or not. Conclusion Ribavirin does not make much difference to mortality in the treatment of SARS and MERS, but it can increase drug safety risks. Thus, the applicability of ribavirin in the treatment of COVID-19 remains to be investigated

Key words: ribavirin, SARS, MERS, COVID-19, SARS, meta-analysis

CLC Number:

R994.1

ZHANG Jin, LIU Ziyun, ZHANG Jun, YANG Jianjun, ZHANG Xiaoyu, JIANG Fengli, WU Yiping, YANG Beibei, LI Xinghuan, CHEN Yuyan, LIU Dong, REN Wei. Meta Analysis of Efficacy and Safety of Ribavirin in the Treatment of COVID-19[J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 393-398.

References

[1] 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第七版)的通知(国卫办医函〔2020〕145号)[EB/OL]. (2020-03-03) [2020-03-04].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[2] 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版)的通知(国卫办医函〔2020〕103号) [EB/OL].(2020-02-04)[2020-02-06].http://www.nhc.gov.cn/yzygj/s7653p/202002/ 3b09b894ac9b4204a79db5b8912d4440.shtml.
[3] 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版修正版)的通知(国卫办医函〔2020〕117号) [EB/OL].(2020-02-08) [2020-02-08]. http://www.nhc.gov.cn/yzygj/s7653p/202002/ d4b895337e19445f8d728fcafle3e13a.shtml.
[4] Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J].Eur J Epidemiol, 2010, 25(9):603-605.
[5] Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0) [EB/OL].(2011-03-20)[2020-02-08]. http://handbook-5-1.cochrane.org/.
[6] Arabi YM, Shalhoub S, Mandourah Y, et al.Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study[J]. Clin Infect Dis,2020, 70(9):1837-1844.
[7] Booth CM, Matukas LM, Tomlinson GA, et al.Clinical Features and Short-term Outcomes of 144 Patients With SARS in the GreaterToronto Area[J]. JAMA, 2003, 289(21):2801-2809.
[8] Almekhlafi GA, Albarrak MM, Mandourah Y, et al.Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients[J].Critical Care, 2016, 20(1):123-131.
[9] Hsu LY, Lee CC, Green JA, et al.Sever acute respiratory syndrome (SARS) in Singapore:clinical features of index patient and initial contacts[J]. Emerging Infectious Diseases, 2003, 9(6):713-717.
[10] Leong HN, Ang B, Earnest A, et al.Investigational use of ribavirin in the treatment of severe acute respiratory syndrome,Singapore,2003[J].Tropical Medicine and International Health, 2004, 9(8):923-927.
[11] Omrani AS, Saad MM, Baig K, et al.Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study[J]. Lancet Infect Dis, 2014,14(11): 1090-1095.
[12] Zhao Z, Zhang F, Xu M, et al.Description and clinical treatment of an early outbreak of severe acute respiratory syndrome(SARS) in Guangzhou, PR China[J]. Journal of Medical Microbiology,2003, 52(8), 715-720.
[13] Cameron CE, Castro C.The mechanism of action of ribavirin:lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase[J]. Curr Opin Infect Dis, 2001,14(6): 757-764.
[14] 利巴韦林注射液说明书[EB/OL].(2015-12-01)[2020-03-04].www.runhongpharm.com/?fpage/i178.
[15] Tsang KW, Ho PL, Ooi GC, et al.A cluster of cases of severe acute respiratory syndrome in Hong Kong[J]. N Engl J Med, 2003,348(20):1977-1985.
[16] Lee N, Hui D, Wu A, et al.A major outbreak of severe acute respiratory syndrome in Hong Kong[J]. N Engl J Med, 2003, 348(20):1986-1994.
[17] Chu CM, Cheng VC, Hung IF, et al.HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings[J]. Thorax, 2004, 59(3):252-256.
[18] 付琦,马秀云,徐艳丽. 利巴韦林治疗SARS患者致心率减慢的病例对照研究[J]. 药物不良反应杂志, 2004, 6(3):154-156.
[19] Morra ME, Van Thanh L, Kamel MG, et al.Clinical outcomes of current medical approaches for Middle East respiratory syndrome:A systematic review and meta-analysis[J]. Rev Med Virol, 2018,28(3):e1977.
[20] Sung JJY, Wu A, Joynt GM, et al.Severe acute respiratorysyndrome: report of treatment and outcome after a major outbreak[J].Tharax, 2004, 59(5):414-420.
[21] Gralinski LE, Menachery VD.Return of the Coronavirus: 2019-nCoV[J]. Viruses, 2020, 12(2): E135.